MedPath

HOSPICES CIVILS DE LYON

HOSPICES CIVILS DE LYON logo
🇫🇷France
Ownership
-
Established
1796-01-01
Employees
10K
Market Cap
-
Website
http://www.chu-lyon.fr

Clinical Trials

1.8k

Active:153
Completed:907

Trial Phases

6 Phases

Early Phase 1:1
Phase 1:99
Phase 2:71
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (983 trials with phase data)• Click on a phase to view related trials

Not Applicable
708 (72.0%)
Phase 1
99 (10.1%)
Phase 2
71 (7.2%)
Phase 3
71 (7.2%)
Phase 4
31 (3.2%)
phase_1_2
1 (0.1%)
Early Phase 1
1 (0.1%)
phase_2_3
1 (0.1%)

New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies.

Not Applicable
Not yet recruiting
Conditions
Toxic Epidermal Necrolysis
Cutaneous Adverse Drug Reactions (CADR)
Immunotherapy
Interventions
Drug: DARATUMUMAB (DARZALEX®)
First Posted Date
2025-08-07
Last Posted Date
2025-08-07
Lead Sponsor
Hospices Civils de Lyon
Target Recruit Count
9
Registration Number
NCT07110662
Locations
🇫🇷

Reference Center for Toxic, Toxin and Toxidermal Bullous Dermatoses - E. Herriot Hospital, Lyon, France

Occurrence of Acute Kidney Injury After CAR-T Cells Treatments in B-cell Lymphoma.

Active, not recruiting
Conditions
Acute Kidney Injury (AKI)
Infusion of CD19 CAR T Cell
B Cell Lymphoma
Interventions
Biological: Incidence of acute kidney injury
Other: Describe risk factors in AKI occurrence.
Other: Focus on patient with chronic kidney disease at baseline
Other: Long term evolution after treatment by CAR-T cells
First Posted Date
2025-08-03
Last Posted Date
2025-08-03
Lead Sponsor
Hospices Civils de Lyon
Target Recruit Count
300
Registration Number
NCT07101913
Locations
🇫🇷

Nephrology department, Centre hospitalier Lyon Sud, Pierre-Bénite, France

Monitoring of Anti-TFPI in Hemophilia

Not yet recruiting
Conditions
Hemophilia
Rebalancing Agents
Prophylaxis
Interventions
Biological: blood sampling
First Posted Date
2025-08-03
Last Posted Date
2025-08-03
Lead Sponsor
Hospices Civils de Lyon
Target Recruit Count
11
Registration Number
NCT07101926
Locations
🇫🇷

Groupement hospitalier Est Hôpital Cardilogique Service d'hémostase clinique, Bron, France

🇫🇷

Centre de Référence Hémophilie et autres déficits rares en protéine de la coagulationCentre de Traitemendes Hémophiles F. Josso, Paris, France

Medium-term Results of Lower Limb Arterial Bypass

Completed
Conditions
Peripheral Arterial Occlusive Disease
Critical Limb Ischemia
Arterial Revascularization
Arterial Bypass Surgery
First Posted Date
2025-07-30
Last Posted Date
2025-07-30
Lead Sponsor
Hospices Civils de Lyon
Target Recruit Count
57
Registration Number
NCT07093632
Locations
🇫🇷

Louis Pradel Cardiology Hospital, Lyon, France

Autonomous Methadone Delivery System by Nurses

Not Applicable
Not yet recruiting
Conditions
Opioid Use Disorder (OUD)
Addictology
First Posted Date
2025-07-25
Last Posted Date
2025-07-25
Lead Sponsor
Hospices Civils de Lyon
Target Recruit Count
182
Registration Number
NCT07085377
Locations
🇫🇷

CSAPA, Association Bizia, Centre Hospitalier de la Côte Basque, Bayonne, France

🇫🇷

CSAPA, Service d'Addictologie, Centre Hospitalier Charles Perrens, CHU de Bordeaux, Bordeaux, France

🇫🇷

CSAPA de Brioude, Brioude, France

and more 5 locations
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 345
  • Next

News

Volition's Nu.Q® Cancer Test Shows Promise in Lung Cancer Screening and Pan-Cancer Detection

Volition has enrolled the first patient in a 500-patient validation study at National Taiwan University Hospital to evaluate Nu.Q® Cancer technology for distinguishing between malignant and benign pulmonary nodules in LDCT lung cancer screening.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.